Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Hodgkin lymphoma
Pharma
ASH: Adcetris, Opdivo boost hopes for another ADC, PD-1 combo
Seagen trotted out new data suggesting its ADC Adcetris could work with BMS' PD-1 drug Opdivo in two classical Hodgkin lymphoma settings.
Angus Liu
Dec 10, 2023 7:30pm
ASCO: Seagen's top-selling drug under threat from Opdivo
Jun 4, 2023 8:00am
ASCO: Will Seagen's Adcetris be a growing force in lymphoma?
May 26, 2022 5:00pm
Seagen aims to win over Adcetris holdouts with key 5-year data
Dec 7, 2020 10:00am
Merck's Keytruda scores solo lymphoma nod after Seagen showdown
Oct 15, 2020 11:34am
Merck's Keytruda beat Adcetris head-to-head. Does it matter?
May 13, 2020 5:00pm
